MMNZ rewards Diamond Dealers in a year of growth
Mitsubishi Motors New Zealand (MMNZ) increased its sales and market share in 2024. Recently it celebrated the standout performers contributing to those results at its annual Diamond Dealer awards. The ceremony was held at the Sheraton Fiji Golf and Beach Resort on May 19.
While the total market fell by 14 per cent last year, MMNZ grew its overall share to 11.7 per cent with 14,156 registrations. That is an almost six per cent increase from the previous calendar year. And it cemented its third-place position.
ASX and Outlander models were the second and third most popular passenger vehicles in 2024. Triton the third most popular light commercial vehicle. Eclipse Cross was the fourth Mitsubishi amongst the top ten, in sixth position.
MMNZ Chief Operating Officer Tony Johnston commented: 'In a challenging market, it's exceptional value and customer service that will help to get you across the line.
'These are both things that customers associate with our brand and which is why, while the broader market contracted, we continued to build momentum.'
That momentum continues into 2025, with MMNZ holding second place in the market with 4116 registrations as of April.
'That's also a testament to the resilience and commitment of our dealers across the country, and the enduring strength of our vehicle range,' said Johnston.
'We never rest on our laurels – as a business or at a dealer level – and the hard work continues across every aspect of sales, parts and service.
'Our annual Diamond Dealer event is an opportunity to recognise and celebrate the very best of our high-achieving teams across the country and incentivise next year's winners.
'I'd like to congratulate our 2025 winners and say a big thank you to all of our dealers and their teams for never losing sight of the fact that our success is only ever measured in the satisfaction and loyalty of our customers.'
2025 Diamond Dealer winners and MMNZ Executive Team at the Sheraton Fiji Golf and Beach Resort
Bay City Mitsubishi
Brendan Foot Mitsubishi
Delaney Mitsubishi
Mexted Mitsubishi
Morrison Mitsubishi Sockburn
Piako Mitsubishi Morrinsville
WR Phillips Mitsubishi
Baigent Motors
Cavanagh Motors
2025 Supreme Diamond Dealer:
Morrison Mitsubishi Sockburn
Mike Morrison
First-time Diamond Dealer Morrison Mitsubishi Sockburn stole the headlines at this year's awards. Having only been in operation since October 2021, Mike Morrison and his team have quickly become standout performers thanks to their high standards and strong community connections.
Morrison Mitsubishi Sockburn is also the 2025 Finance Dealer of the Year and finished top of its group for Customer Service Excellence.
Piako Mitsubishi Morrinsville – Darrell Russell
Darrell Russell and his team at Piako Mitsubishi Morrinsville continue to punch above their weight. This year's success means Darrell now has an unsurpassed 17 Diamond Dealer awards to his name. He has also topped the charts for New Vehicle Sales in his group. The success of the dealership is rooted in a rural community with just 11,000 inhabitants, making this an even more remarkable story.
Brendan Foot Mitsubishi – Dave Foot
After going back-to-back in 2021 and 2022, Brendan Foot Mitsubishi makes a well-deserved return as a Diamond Dealer. Dave Foot and his team return, also taking home Top Market Share for their group.
Mexted Mitsubishi – Nicole & Mark Munkittrick
After getting a taste for success in 2024, Mexted Mitsubishi – based in Tawa, is back for more. Nicole and Mark took over the dealership four years ago and have rapidly proved their worth as Diamond Dealers. Mexted Mitsubishi also won Top Market Share for its group.
WR Phillips – Paul & Julia Phillips
WR Phillips has now won five Diamond Dealer titles in a row, thanks to strong performances across the board and a deep connection to its New Plymouth community. Paul and Julia also had the highest sales number in their group for a second consecutive year.
Delaney Mitsubishi – Brent & Rachel Delaney
With a string of parts and service awards to their name, Brent and Rachel Delaney added vehicle sales to their Kapiti Coast dealership in 2021 and won their first Diamond Dealer title last year. They're back for more with a second-consecutive award – and also took home the Overall Parts Excellence award.
Bay City Mitsubishi – Aaron Chatfield
Aaron Chatfield is one of the most successful dealers in the MMNZ network. With 16 Diamond Dealer awards to his name (12 in a row) and consecutive Supreme Diamond Dealer awards between 2023-2024, his Bay City team continues to set the standard in a competitive region.
Baigent Motors – Justin Scelly
As MMNZ's most awarded parts and service dealer, Justin Scelly oversees an exceptional team that now has a seventh Diamond Dealer award in a row to its name. They set a high bar for all parts and service teams across the country.
Cavanagh Motors – Bruce Jensen
With a new visual identity installed, Bruce and his Cavanagh Motors team hope their Diamond Dealer award for parts and service is the first of many, proving there's more to Te Puke than kiwifruit and honeybees.
Overall Service Excellence
Andrew Simms Mitsubishi Newmarket
Overall Parts Excellence
Delaney Mitsubishi
Customer Excellence Award
Peter Keown Automotive
Finance Dealer of the Year
Morrison Mitsubishi Sockburn
Customer Service Excellence
Group 1: Morrison Mitsubishi Sockburn
Group 2: McVerry Crawford Mitsubishi Palmerston North
Group 3: Delaney Mitsubishi
Top New Vehicle Sales
Group 1: Andrew Simms Mitsubishi Newmarket
Group 2: W.R. Phillips Mitsubishi
Group 3: Piako Mitsubishi Morrinsville
Top Market Share
Group 1: Brendan Foot Mitsubishi
Group 2: Mexted Motors Mitsubishi
Group 3: Archibald Motors
Managing Director's Award
Stefan Cooper, Ingham Mitsubishi Te Awamutu
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
2 days ago
- Scoop
Pacific Edge Reports Resilient Performance In FY25
Press Release – Pacific Edge Pacific Edge also announces a NZ$20 million equity raising to capitalize on recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage. The details of the capital raising are covered in a separate announcement … AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2025 30 May 2025 Pacific Edge today reports a resilient financial result for the year to the end of March 2025. Improvements in the performance of the sales force, operating efficiencies and cash collection gains over the financial year have positioned the company well as it works towards regaining Medicare coverage of its tests. Pacific Edge today also announces a NZ$20 million equity raising to capitalize on recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage. The details of the capital raising are covered in a separate announcement to the NZX and ASX today. FY25 FINANCIAL PERFORMANCE2 Operating revenue down 8.6% on FY 24 to $21.8 million, reflecting Medicare uncertainty. Total revenue is down 16% on FY 24 to $24.6 million Total laboratory throughput3 (TLT) of Cxbladder tests fell 11.5% on FY 24 to 28,894; commercial tests fell 9.9% on FY 24 to 26,42 tests Tests/Sales FTE in the US for Q4 25 were reported at 405.6, up 6.4% on Q4 24; ASP4 for all commercial tests in the US increases to US$594 in FY 25 vs US$584 in FY 24 as operating efficiencies and cash collection gains continue to improve Strong performance from the Southern California Permanente Medical Group, increased APAC volume and sustained sales force efficiencies reduce the impact of Medicare uncertainty and the reduced sales team reach Net loss after tax +1.4% on FY 24 to $29.9 million, 2H 25 net loss +6.4% on 1H 25 led by increased expenditure on clinical research, Triage Plus commercialization and legal fees Cash, cash equivalents and short-term deposits of $22.6 million at the end of FY25; cash burn of $13.4 million in 2H 25 down 6.7% on 1H 25 FY 25 STRATEGIC PERFORMANCE Cxbladder Triage included in the American Urological Association (AUA) guidelines with a 'Grade A' evidence rating, the only biomarker to achieve this status Triage Plus achieves a draft Medicare price of US$1,018.44, a significant premium to the current US$760 per test; full scale commercial launch is now contingent on re-coverage Medicare coverage discontinued following Genetic Tests for Oncology (Specific Tests) (L39365) becoming effective after balance date (24 April 2025); Pacific Edge is now focused on regaining coverage for Triage and Monitor and obtaining coverage and launch of new products Triage Plus and Monitor Plus Commercial team focused on profitable territories, non-Medicare revenue streams and selling the clinical and economic value of Cxbladder; Cxbladder Detect discontinued FY25 Climate Disclosures released in compliance with NZCS NOTE: PEB HAS RELEASED THIS UPDATE TO THE NZX AND ASX AS PER LISTING RULES [1] 1 PEB has released the information contained in this update to the NZX and ASX as it regards it to be material, as defined in the NZX Listing Rules and Section 231 of the FMC Act. 2 All comparisons are to the same period of the prior financial year unless otherwise stated. 3 Total Laboratory Throughput (TLT) includes commercial, pre-commercial and clinical studies testing. 4 ASP: US Average Sales Price (US Operating Revenue in USD / US Commercial Test Volumes)
Scoop
2 days ago
- Scoop
Pacific Edge Reports Resilient Performance In FY25
AUDITED FINANCIAL RESULTS FOR THE YEAR TO 31 MARCH 2025 30 May 2025 Pacific Edge today reports a resilient financial result for the year to the end of March 2025. Improvements in the performance of the sales force, operating efficiencies and cash collection gains over the financial year have positioned the company well as it works towards regaining Medicare coverage of its tests. Pacific Edge today also announces a NZ$20 million equity raising to capitalize on recent clinical and commercial milestones, grow in non-Medicare channels and regain Medicare coverage. The details of the capital raising are covered in a separate announcement to the NZX and ASX today. FY25 FINANCIAL PERFORMANCE2 Operating revenue down 8.6% on FY 24 to $21.8 million, reflecting Medicare uncertainty. Total revenue is down 16% on FY 24 to $24.6 million Total laboratory throughput3 (TLT) of Cxbladder tests fell 11.5% on FY 24 to 28,894; commercial tests fell 9.9% on FY 24 to 26,42 tests Tests/Sales FTE in the US for Q4 25 were reported at 405.6, up 6.4% on Q4 24; ASP4 for all commercial tests in the US increases to US$594 in FY 25 vs US$584 in FY 24 as operating efficiencies and cash collection gains continue to improve Strong performance from the Southern California Permanente Medical Group, increased APAC volume and sustained sales force efficiencies reduce the impact of Medicare uncertainty and the reduced sales team reach Net loss after tax +1.4% on FY 24 to $29.9 million, 2H 25 net loss +6.4% on 1H 25 led by increased expenditure on clinical research, Triage Plus commercialization and legal fees Cash, cash equivalents and short-term deposits of $22.6 million at the end of FY25; cash burn of $13.4 million in 2H 25 down 6.7% on 1H 25 FY 25 STRATEGIC PERFORMANCE Cxbladder Triage included in the American Urological Association (AUA) guidelines with a 'Grade A' evidence rating, the only biomarker to achieve this status Triage Plus achieves a draft Medicare price of US$1,018.44, a significant premium to the current US$760 per test; full scale commercial launch is now contingent on re-coverage Medicare coverage discontinued following Genetic Tests for Oncology (Specific Tests) (L39365) becoming effective after balance date (24 April 2025); Pacific Edge is now focused on regaining coverage for Triage and Monitor and obtaining coverage and launch of new products Triage Plus and Monitor Plus Commercial team focused on profitable territories, non-Medicare revenue streams and selling the clinical and economic value of Cxbladder; Cxbladder Detect discontinued FY25 Climate Disclosures released in compliance with NZCS NOTE: PEB HAS RELEASED THIS UPDATE TO THE NZX AND ASX AS PER LISTING RULES [1] 1 PEB has released the information contained in this update to the NZX and ASX as it regards it to be material, as defined in the NZX Listing Rules and Section 231 of the FMC Act. 2 All comparisons are to the same period of the prior financial year unless otherwise stated. 3 Total Laboratory Throughput (TLT) includes commercial, pre-commercial and clinical studies testing. 4 ASP: US Average Sales Price (US Operating Revenue in USD / US Commercial Test Volumes)
National Business Review
4 days ago
- National Business Review
IkeGPS predicts punchy revenue growth for FY26
IkeGPS saw subscription revenue grow by 34% in FY25 and expects to reach above that level again in the current financial year as it pushes for its technology to become the industry standard in the North American market. The NZX- and ASX-listed company, whose technology helps utilities such as lines
